Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids.
- DOI
- 10.1158/1535-7163.mct-26-0200
- Published
- 2026 Oct 7
- Container
- Molecular cancer therapeutics
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/1535-7163.mct-26-0200,
title = {Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids.},
author = {Dexheimer TS and Davoudi Z and Coussens NP and Silvers T and Jones EM and Takebe N and Doroshow JH and Teicher BA},
year = {2026},
journal = {Molecular cancer therapeutics},
doi = {10.1158/1535-7163.mct-26-0200},
url = {https://doi.org/10.1158/1535-7163.mct-26-0200}
}RIS
TY - JOUR TI - Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids. AU - Dexheimer TS AU - Davoudi Z AU - Coussens NP AU - Silvers T AU - Jones EM AU - Takebe N AU - Doroshow JH AU - Teicher BA PY - 2026 JO - Molecular cancer therapeutics DO - 10.1158/1535-7163.mct-26-0200 UR - https://doi.org/10.1158/1535-7163.mct-26-0200 ER -
APA
TS, D., Z, D., NP, C., T, S., EM, J., N, T., JH, D., & BA, T. (2026). Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids.. Molecular cancer therapeutics. https://doi.org/10.1158/1535-7163.mct-26-0200
Source records
- pubmed · retrieved 2026-11-10T14:37:59.004Z
- pubmed · retrieved 2026-11-10T14:37:59.004Z
- europe-pmc · retrieved 2026-11-10T14:37:59.003Z
- europe-pmc · retrieved 2026-11-10T14:37:59.003Z